WINDLAS BIOTECH IPO REVIEW AND GMP DETAILS:
Windlas Biotech Is the Top Pharmaceutical Lead Company In India. Windlas Biotech Is Working on Manufacture Medicine And Other Biotech Products. This Company Not Perches Medicine To Other Pharma Company. They Owen Manufacture Medicine And Pharma Products. Windlas Biotech Also Works on Commercial Manufacturing, development, And licensing. This Company Working On Pharma Marketing on Domestic And International Level. This Is a Good Way Of This Company.
Top Indian Pharma Company Is Cadila, Pfizer, Intas Pharmaceuticals, Windlas Biotech, Systopic Laboratories Etc. All Top Pharma Company Listed In BSE and NSE And Good Perform in This Pandemic. Now This Company Also Listed In This Month. Expected This Company Good Perform.
WINDLASS BIOTECH COMPANY LOCATION IN INDIA:
This Company Manufacturing Plant Located on Dehradun Uttarakhand. All Type Of Medicine Manufacturing on This Plant. Tablets And Capsules Capacity is 7,063.83 million, Sachet And Pouch Capacity Are 54.46 M. This Company Is Good Working on CDMO. This Company Supply His Health And Pharma Products On International Market. This Company Most Focus on Domestic Market And International Market.
Windlas Biotech Good Revenue Earn By Foreign Countries. This Company Gives Good Quality To Its clients. This Company Good Perform In Future. Demand Of Medicine Increase And Generated Good Revenue. This Is a Good Company For Long Term.
GOOD FOCUS POINT OF WINDLAS BIOTECH:
- Good and Intelligent Management Team.
- Long Term Focus on Pharma Sector
- Promoters And Investor Available.
- Strong Portfolio Available
PROMOTERS AND INVESTOR HOLDING:
- Ashok, Hitesh, And Manoj Windlas.
- Windlass Family.
- AKW Family
FINANCIAL REPORT OF WINDLAS BIOTECH:
|Profit After Tax||638.22||162.13||96.74|
Financial Report. Windlas
WINDLAS IPO DETAILS:
|IPO Open Date||Aug 4, 2021|
|IPO Close Date||Aug 5, 2021|
|Type Of Issue||Book Built IPO|
|Price Of IPO||₹448 to ₹460 Per share|
|Listing Platform||BSE, NSE|
|Size Issue||₹401.54 Cr|
|Fresh Issue||₹165.00 Cr|
|Sale Price||₹236.54 Cr|
Windlas IPO Is Good IPO In Indian Gray Market. This Sector Is Good Performed. QIB, NII, RII Subscribe This IPO By Low at This Moment Price. This IPO Issue Size is ₹401.54 Cr and the Fresh Issue Size is 165.00 Cr. Windlas Issue Sale Price Is 236.54 Cr.
Windlas Is a Profitable Company. This IPO Is Give Avg Profit.
WINDLAS IPO SCHEDULE:
|Credit Stock In Account||13/08/2021|
Windlas Biotech IPO Open Date is 04 AUG and Close Date Is 06 AUG. Allotment Date of This IPO Is Aug 11 and Refund Is Unblock In Bank Account Aug 12. Stock Credit In Demate Account on Aug 13 Than IPO Is Listing In BSE and NSE Platform on Aug 17, 2021. Trading Start in This Company at 10:00 am.
WINDLAS BIOTECH IPO LOT SIZE:
This IPO Min Lot Size 1 (30 Quantity in one Lot) and Price of One Lot (448 to 460) So Total Amount is (13,440 to 13,800).
Max Lot Size 14 (30 Quantity in one Lot) Total Amount Is (188,160 to 193,200).
This Company is one of the Good Pharma And Other Bio Companies Listed on BSE and NSE So This Company Gives Good Long Term Returns for its Share Holders. This Is a Avg Good Future Profitable Company. Big Stock Player Also Invested in Windlas For Long Term and According To Rumors Investor are High h0ld This Stock For Long Term.
IPO SUBSCRIBE DETAILS OF WINDLAS BIOTECH:
Live ON(04/08/2021) Time (10:00).
|Category||IPO Subscribe Rate|
|QIB (Qualified Institutional Buyer)||24.40 MULTIPLE TIME|
|NII (Non-Institutional Investor)||15.70 MULTIPLE TIME|
|RII (Retail Individual Investor)||24.22 MULTIPLE TIME|
|Total Subscribe||22.44 MULTIPLE TIME|
GRAY MARKET PREMIUM OF WINDLAS:
Windlas Today Gray Market Premium Is 170 Rupees Is Avg Premium Rate. Around 48% Premium Running. Premium Rate Are Going High in This IPO. Big Company IPO Coming So Good Performance Give This IPO in Long Term.
How To Check IPO Allotment Details:
Windlas IPO Allotment Check By BSE Website:- Not Available
Windlas IPO Partner Company Website:- No Available.
Rolex Ring IPO Details Check.
#Note:- This All Content Provide Only Education And Information Purpose. We Are Not Trade-In Gray Market. We Are Provide Only Information. Consult Your Advisor Before Investing.